Weitz & Luxenberg Recognizes New Advance in Mesothelioma Treatment

NEW YORK--(BUSINESS WIRE)--Dec 17, 2007 - Research hospitals in Europe have successfully tested a new anticancer drug, "Vinflunine" (pronounced VIN-floo-neen). The October 20th issue of Journal of Clinical Oncology featured the news that Vinflunine has been shown to improve response and survival rates in patients diagnosed with malignant pleural mesothelioma, according to Reuters.

Mesothelioma is a rare, deadly form of cancer that affects the inside lining of the chest cavity and is directly associated with asbestos exposure.

Of the promise Vinflunine could hold, Ben Darche, an attorney with the Asbestos Litigation Unit at Weitz & Luxenberg, P.C., said, "We commend the medical advances being made by Dr. Denis C. Talbot and his colleagues. Through my work I have witnessed the emotional and financial suffering mesothelioma places on patients and their families. Any medical advance is no small miracle."

Weitz & Luxenberg, P.C., commends this recent medical advance and the doctors that achieved it. During many years of representing clients suffering from mesothelioma, Weitz & Luxenberg has seen first-hand the pain and suffering the disease has on victims and their loved ones. Most mesothelioma patients, for example, die within one year of being diagnosed. There is no known cure for mesothelioma.

Vinflunine was recently tested in Phase II clinical trials at hospital research centers in England and France. Dr. Talbot, from the Churchill Hospital in Oxford, and medical colleagues at seven European hospital centers, assessed the response rates of 67 patients who had not received prior chemotherapy or radiotherapy to determine the effectiveness of first-line Vinflunine treatment.

Doctors concluded that Vinflunine, when administered approximately every 21 days in high doses, improved patients' response rates by 13.8 percent, and demonstrated such positive results that the drug therapy warrants further evaluation. In 2004, the Food and Drug Administration approved the first drug for this condition, "Alimta," which, when used in combination with cisplatin, has helped patients extend their lives by several months, according to the FDA.

About 2,000 cases of mesothelioma are diagnosed in the United States every year, based on statistics from the National Cancer Institute. Current treatments are limited and usually include some form of surgery, combined with chemotherapy or radiation. The disease, which is often linked to industrial workplace exposure to asbestos, is usually contracted through employers' disregard for health safety.

Weitz & Luxenberg specializes in the prosecution of asbestos-related work cases and has won many multi-million-dollar verdicts and settlements for victims' families to help them offset medical expenses and compensate for suffering. In 2006, the firm secured a $25 million jury verdict in a trial against DaimlerChrysler AG for a New York City brake reliner who lost his right lung to mesothelioma. Weitz & Luxenberg's successes date back to 1991 with a historic consolidated trial involving men who worked at the Brooklyn Navy Yard during and after World War II. Weitz & Luxenberg represented 36 clients in that case, securing a verdict of $75 million.

Weitz & Luxenberg offers free case reviews from www.weitzlux.com.

People who have been harmed by asbestos or wish to know more about the threat can contact Weitz & Luxenberg by visiting the firm's Web site at www.weitzlux.com.

About Weitz & Luxenberg, P.C.

Weitz & Luxenberg, founded in 1986, is one of the leading plaintiffs' law firms in America. The firm has also played leading roles in national and local litigations involving asbestos, DES, silicone breast implants, medical malpractice, and general negligence, among others. A forerunner in the legal fight against environmental polluters, Weitz & Luxenberg has worked with clients harmed by MTBE and mercury, among other toxins. The firm has won numerous cases involving dangerous pharmaceuticals, including Vioxx, achieving a $13.5 million verdict against Merck & Co. The firm's other active pharmaceutical litigations include actions against the manufacturers of Bextra, ReNu, Celebrex, Ortho Evra and Seroquel.

Contact

Weitz & Luxenberg
Client Relations, 1-800-476-6070
clientrelations@weitzlux.com
www.weitzlux.com

Posted: December 2007

View comments

Hide
(web2)